The DOI matches its Crossref record.
Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
Abstract
BACKGROUND: Treatment of hepatitis C virus (HCV) has become a major challenge in HIV-infected individuals. No data exist on the efficacy and tolerability of pegylated IFN (peg-IFN) plus ribavirin in HIV-co-infected patients. METHODS: Subcutaneous peg-IFN (150 microg weekly during the first 12 weeks and 100 microg weekly thereafter) plus ribavirin (400 mg twice a day) was given to 68 HIV-infected patients with chronic hepatitis C, having CD4 cell counts greater than 300 cells/microl, plasma HIV-RNA less than 5000 copies/ml, and elevated aminotransferase levels. All were naive for IFN, and 73% were receiving antiretroviral drugs. RESULTS: Plasma HCV-RNA levels greater than 800 000 IU/ml were seen in 50%, and 35% carried HCV genotype 3. Adverse events leading to treatment discontinuation occurred in 10 patients (15%). One patient taking didanosine developed pancreatitis. Severe weight loss occurred in 70% of patients. Clearance of HCV-RNA at the end of therapy (6 months for HCV-3 and 12 months for HCV-1/4) occurred in 50% of patients (81% with HCV-3 versus 30% with HCV-1/4). As 30% relapsed, the overall sustained response rate was 35% (28% in the intent-to-treat analysis). The main predictors of response were infection with HCV-3 and low HCV load. CONCLUSION: Treatment with peg-IFN and ribavirin is relatively well-tolerated in HIV/HCV-co-infected patients, although new side-effects, including pancreatitis and severe weight loss, may result from the interaction of ribavirin with antiretroviral drugs. Overall, therapy provides cure to one third of patients, a rate significantly lower than that seen in HCV-monoinfected individuals. Given that relapses are common, extended periods of therapy should be investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Laguno, M., Murillas, J., Blanco, J. L., Martínez, E., Miquel, R., Sánchez-Tapias, J. M., Bargallo, X., García-Criado, A., Lazzari, E. D., Larrousse, M., et al. (2004) · AIDS · doi:10.1097/00002030-200409030-00003 · Cited by 387
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters, M., Mauss, S., Bräu, N., Hatzakis, A., Pol, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3281084e4d · Cited by 349
Self-citation
Metadata
- Authors
- Pérez-Olmeda, M., Núñez, M., Romero, M., González, J., Castro, A., Arribas, J. R., Pedreira, J., Barreiro, P., García-Samaniego, J., Martín-Carbonero, L., Jiménez-Nácher, I., & Soriano, V.
- Venue
- AIDS
- Published
- 2003-05
- Volume
- 17
- Issue
- 7
- Pages
- 1023-1028
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2000674705
- Cited by
- 200
- References
- 0
- FWCI
- 24.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. https://app.cochat.ai/papers/10.1097/00002030-200305020-00011
- The paper
- Pérez-Olmeda, M., Núñez, M., Romero, M., González, J., Castro, A., Arribas, J. R., Pedreira, J., Barreiro, P., García-Samaniego, J., Martín-Carbonero, L., Jiménez-Nácher, I., & Soriano, V. (2003). Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. https://doi.org/10.1097/00002030-200305020-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.